SEC Filing Summary: Labstyle Innovations Corp. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Labstyle Innovations Corp. on December 22, 2015. The registrant, incorporated in Delaware, is based in Caesarea Industrial Park, Israel. The report addresses a regulatory milestone for the company's Dario Blood Glucose Monitoring System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the receipt of 510(k) clearance from the United States Food and Drug Administration (FDA) for the Dario Blood Glucose Monitoring System. This clearance covers the following components:
- Dario Blood Glucose Meter
- Dario Blood Glucose Test Strips
- Dario Glucose Control Solutions
- Dario app on the Apple iOS 6.1 platform and higher
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, or contingencies beyond the announcement of the FDA clearance. No unusual items were disclosed.
Investor Verification Checklist
- Verify the scope of the FDA 510(k) clearance to confirm it applies to all listed components (meter, strips, solutions, and app).
- Confirm the specific iOS version compatibility (6.1 and higher) for the Dario app.
- Review subsequent filings for commercial launch dates and revenue impact resulting from this clearance.
- Check for any post-clearance regulatory conditions or limitations not detailed in this summary.